USD 4.57
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| GDRX | 3.4 | 4.8 | 2.9 | -30.9 | -46.2 | -30.4 | -80.6 | -91.0 | -91.0 | -91.0 |
| S&P 500 | 1.0 | 0.6 | 1.1 | 2.4 | 8.9 | 23.6 | 36.4 | 80.6 | 195.1 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | GDRX |
| name | GoodRx Holdings, Inc. |
| price | 4.57 |
| changes percentage | 3.3937 |
| change | 0.15 |
| day low | 4.38 |
| day high | 4.61 |
| year high | 9.26 |
| year low | 4.09 |
| market cap | 1741818318 |
| price avg 50 | 4.6932 |
| price avg 200 | 6.788 |
| exchange | NASDAQ |
| volume | 1841673 |
| avg volume | 1446234 |
| open | 4.42 |
| previous close | 4.42 |
| eps | -0.04 |
| pe | -114.25 |
| earnings announcement | 2025-02-26T13:30:00.000+0000 |
| shares outstanding | 381141864 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001809519 | |||
| revenue | 750265000 | 766554000 | -2.12 |
| gross profit | 683340000 | 701475000 | -2.59 |
| gross profit ratio | 0.91 | 0.92 | -0.47 |
| research and development expenses | 135836000 | 143137000 | -5.10 |
| operating expenses | 710347000 | 699737000 | 1.52 |
| interest income | 32171000 | 9274000 | 246.89 |
| interest expense | 56728000 | 34243000 | 65.66 |
| ebitda | 108824000 | 68538000 | 58.78 |
| ebitdaratio | 0.15 | 0.09 | 70.56 |
| operating income | -27007000 | 11012000 | -345.25 |
| operating income ratio | -0.04 | 0.01 | -350.58 |
| net income | -8868000 | -32828000 | 72.99 |
| net income ratio | -0.01 | -0.04 | 72.40 |
| eps | -0.02 | -0.08 | 72.83 |
Revenue Growth: revenue decreased to 750 million in 2023 from 767 million in 2022 representing a change of -2.12%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 683 million in 2023 from 701 million in 2022 representing a change of -2.59%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 136 million in 2023 from 143 million in 2022 representing a change of -5.1%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 710 million in 2023 from 700 million in 2022 representing a change of 1.52%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 109 million in 2023 from 69 million in 2022 representing a change of 58.78%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -27 million in 2023 from 11 million in 2022 representing a change of -345.25%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income increased to -9 million in 2023 from -33 million in 2022 representing a change of 72.99%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.02 in 2023 from -0.02 in 2022 representing a change of 72.83%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001809519 | |||
| revenue | 195251000 | 200610000 | -2.67 |
| gross profit | 183567000 | 171775000 | 6.86 |
| gross profit ratio | 0.94 | 0.86 | 9.80 |
| research and development expenses | 30139000 | 30854000 | -2.32 |
| operating expenses | 163160000 | 151157000 | 7.94 |
| interest income | 4797000 | 6334000 | -24.27 |
| interest expense | 12355000 | 14566000 | -15.18 |
| ebitda | 38002000 | 36843000 | 3.15 |
| ebitdaratio | 0.19 | 0.19 | 3.89 |
| operating income | 20407000 | 20618000 | -1.02 |
| operating income ratio | 0.1 | 0.1 | 1.69 |
| net income | 12259000 | 6694000 | 83.13 |
| net income ratio | 0.06 | 0.03 | 88.16 |
| eps | 0.03 | 0.02 | 81.46 |
Revenue Growth: revenue decreased to 195 million in 2024Q3 from 201 million in 2024Q2 representing a change of -2.67%. This indicates a sales shrinking, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 30 million in 2024Q3 from 31 million in 2024Q2 representing a change of -2.32%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 163 million in 2024Q3 from 151 million in 2024Q2 representing a change of 7.94%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to 20 million in 2024Q3 from 21 million in 2024Q2 representing a change of -1.02%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 12 million in 2024Q3 from 7 million in 2024Q2 representing a change of 83.13%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Gross Profit: Gross Profit increased to 184 million in 2024Q3 from 172 million in 2024Q2 representing a change of 6.86%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 38 million in 2024Q3 from 37 million in 2024Q2 representing a change of 3.15%. The increase in EBITDA indicates improved operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to 0.03 in 2024Q3 from 0.03 in 2024Q2 representing a change of 81.46%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001809519 | |||
| total assets | 1588800000 | 1604631000 | -0.99 |
| total liabilities | 826842000 | 789804000 | 4.69 |
| total equity | 761958000 | 814827000 | -6.49 |
| cash and cash equivalents | 672296000 | 757165000 | -11.21 |
| short term investments | 0 | 0 | NaN |
| long term investments | 15000000 | 19000000 | -21.05 |
| total current assets | 872790000 | 919686000 | -5.10 |
| total non current assets | 716010000 | 684945000 | 4.54 |
| total current liabilities | 122559000 | 76320000 | 60.59 |
| total non current liabilities | 704283000 | 713484000 | -1.29 |
| common stock | 40000 | 40000 | 0.00 |
| retained earnings | -1457403000 | -1448535000 | -0.61 |
| total debt | 711070000 | 717024000 | -0.83 |
Total Assets: Total Assets decreased to 1,589 million in 2023 from 1,605 million in 2022 representing a change of -0.99%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 827 million in 2023 from 790 million in 2022 representing a change of 4.69%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 762 million in 2023 from 815 million in 2022 representing a change of -6.49%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 672 million in 2023 from 757 million in 2022 representing a change of -11.21%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 873 million in 2023 from 920 million in 2022 representing a change of -5.1%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 123 million in 2023 from 76 million in 2022 representing a change of 60.59%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,457 million in 2023 from -1,449 million in 2022 representing a change of -0.61%. This indicates an accumulated losses.
Total Debt: Total Debt decreased to 711 million in 2023 from 717 million in 2022 representing a change of -0.83%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001809519 | |||
| total assets | 1354846000 | 1475390000 | -8.17 |
| total liabilities | 658412000 | 805991000 | -18.31 |
| total equity | 696434000 | 669399000 | 4.04 |
| cash and cash equivalents | 423777000 | 524903000 | -19.27 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 15000000 | -100.00 |
| total current assets | 626800000 | 750555000 | -16.49 |
| total non current assets | 728046000 | 724835000 | 0.44 |
| total current liabilities | 114361000 | 102473000 | 11.60 |
| total non current liabilities | 544051000 | 703518000 | -22.67 |
| common stock | 38000 | 38000 | 0.00 |
| retained earnings | -1447753000 | -1451718000 | 0.27 |
| total debt | 56974000 | 707381000 | -91.95 |
Total Assets: Total Assets decreased to 1,355 million in 2024Q3 from 1,475 million in 2024Q2 representing a change of -8.17%. Suggesting a decrease in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 424 million in 2024Q3 from 525 million in 2024Q2 representing a change of -19.27%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 627 million in 2024Q3 from 751 million in 2024Q2 representing a change of -16.49%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 114 million in 2024Q3 from 102 million in 2024Q2 representing a change of 11.6%. This indicates a higher short-term debt burden.
Total Liabilities: Total Liabilities decreased to 658 million in 2024Q3 from 806 million in 2024Q2 representing a change of -18.31%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 696 million in 2024Q3 from 669 million in 2024Q2 representing a change of 4.04%. This indicates an increase in shareholders' equity.
Retained Earnings: Retained Earnings increased to -1,448 million in 2024Q3 from -1,452 million in 2024Q2 representing a change of 0.27%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 57 million in 2024Q3 from 707 million in 2024Q2 representing a change of -91.95%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001809519 | |||
| net change in cash | -84869000 | -183944000 | 53.86 |
| operating cash flow | 138292000 | 146780000 | -5.78 |
| free cash flow | 82526000 | 91566000 | -9.87 |
| capital expenditure | -55766000 | -55214000 | -1.00 |
| depreciation and amortization | 111772000 | 54177000 | 106.31 |
| deferred income tax | -65562000 | -497000 | -13091.55 |
| stock based compensation | 104820000 | 120234000 | -12.82 |
| accounts payables | 17456000 | -874000 | 2097.25 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -155284000 | 100.00 |
| investments in property plant and equipment | -1043000 | -55214000 | 98.11 |
| net cash used for investing activites | -55766000 | -210498000 | 73.51 |
| debt repayment | -5271000 | -7029000 | 25.01 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -103974000 | -101721000 | -2.21 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -167395000 | -120226000 | -39.23 |
| cash at end of period | 672296000 | 757165000 | -11.21 |
| accounts receivables | -26467000 | 1375000 | -2024.87 |
| cash at beginning of period | 757165000 | 941109000 | -19.55 |
Net Change in Cash: Net Change in Cash increased to -85 million in 2023 from -184 million in 2022 representing a change of 53.86%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -56 million in 2023 from -55 million in 2022 representing a change of -1.0%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 105 million in 2023 from 120 million in 2022 representing a change of -12.82%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -26 million in 2023 from 1 million in 2022 representing a change of -2024.87%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to 138 million in 2023 from 147 million in 2022 representing a change of -5.78%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 83 million in 2023 from 92 million in 2022 representing a change of -9.87%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 17 million in 2023 from 1 million in 2022 representing a change of 2097.25%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001809519 | |||
| operating cash flow | 86862000 | 9701000 | 795.39 |
| free cash flow | 71003000 | -7528000 | 1043.19 |
| capital expenditure | -15859000 | -17229000 | 7.95 |
| depreciation and amortization | 17535000 | 16965000 | 3.36 |
| deferred income tax | -642000 | 4952000 | -112.96 |
| stock based compensation | 26381000 | 26590000 | -0.79 |
| accounts receivables | 30971000 | -17005000 | 282.13 |
| accounts payables | -5150000 | -15565000 | 66.91 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 36766000 | -17229000 | 313.40 |
| net cash used for investing activites | -15859000 | -17229000 | 7.95 |
| debt repayment | -161732000 | -1757000 | -9105.01 |
| common stock issued | 0 | 9188000 | -100.00 |
| common stock repurchased | -5431000 | -9152000 | 40.66 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -172129000 | -864000 | -19822.34 |
| net change in cash | -101126000 | -8391999 | -1105.03 |
| cash at end of period | 423777000 | 524903000 | -19.27 |
| cash at beginning of period | 524903000 | 533294999 | -1.57 |
Net Change in Cash: Net Change in Cash decreased to -101 million in 2024Q3 from -8 million in 2024Q2 representing a change of -1105.03%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to -16 million in 2024Q3 from -17 million in 2024Q2 representing a change of 7.95%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Receivables: Accounts Receivables increased to 31 in 2024Q3 from -17 million in 2024Q2 representing a change of 282.13%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to 87 million in 2024Q3 from 10 million in 2024Q2 representing a change of 795.39%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 71 million in 2024Q3 from -8 million in 2024Q2 representing a change of 1043.19%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 26 million in 2024Q3 from 27 million in 2024Q2 representing a change of -0.79%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 5 million in 2024Q3 from 16 million in 2024Q2 representing a change of 66.91%. This indicates that the company has reduced its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 1.83 | 1.86 | -1.52 |
| net income per share | -0.02 | -0.08 | 72.82 |
| operating cash flow per share | 0.34 | 0.36 | -5.20 |
| free cash flow per share | 0.2 | 0.22 | -9.31 |
| cash per share | 1.64 | 1.83 | -10.66 |
| book value per share | 1.86 | 1.97 | -5.91 |
| tangible book value per share | 0.47 | 0.52 | -7.86 |
| shareholders equity per share | 1.86 | 1.97 | -5.91 |
| interest debt per share | 1.87 | 1.82 | 2.83 |
| market cap | 2749110500 | 1923918280 | 42.89 |
| enterprise value | 2787884500 | 1883777280 | 47.99 |
| pe ratio | -310.0 | -58.61 | -428.96 |
| price to sales ratio | 3.66 | 2.51 | 45.99 |
| pocfratio | 19.88 | 13.11 | 51.66 |
| pfcf ratio | 33.31 | 21.01 | 58.54 |
| pb ratio | 3.61 | 2.36 | 52.81 |
| ptb ratio | 3.61 | 2.36 | 52.81 |
| ev to sales | 3.72 | 2.46 | 51.21 |
| enterprise value over ebitda | 25.62 | 27.49 | -6.79 |
| ev to operating cash flow | 20.16 | 12.83 | 57.08 |
| ev to free cash flow | 33.78 | 20.57 | 64.21 |
| earnings yield | -0.0 | -0.02 | 81.10 |
| free cash flow yield | 0.03 | 0.05 | -36.93 |
| debt to equity | 0.93 | 0.88 | 6.05 |
| debt to assets | 0.45 | 0.45 | 0.16 |
| net debt to ebitda | 0.36 | -0.59 | 160.84 |
| current ratio | 7.12 | 12.05 | -40.90 |
| interest coverage | -0.48 | 0.32 | -248.04 |
| income quality | -15.59 | -4.47 | -248.78 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.17 | 0.19 | -11.43 |
| research and ddevelopement to revenue | 0.18 | 0.19 | -3.04 |
| intangibles to total assets | 0.36 | 0.38 | -4.87 |
| capex to operating cash flow | 0.4 | 0.38 | 7.20 |
| capex to revenue | 0.07 | 0.07 | 3.19 |
| capex to depreciation | 0.5 | 1.02 | -51.04 |
| stock based compensation to revenue | 0.14 | 0.16 | -10.93 |
| graham number | 0.95 | 1.88 | -49.43 |
| roic | -0.0 | 0.01 | -128.86 |
| return on tangible assets | -0.01 | -0.03 | 73.49 |
| graham net net | -0.08 | 0.13 | -162.89 |
| working capital | 750231000 | 843366000 | -11.04 |
| tangible asset value | 194852000 | 212773000 | -8.42 |
| net current asset value | 45948000 | 129882000 | -64.62 |
| invested capital | 1363198000 | 1501146000 | -9.19 |
| average receivables | 138593000 | 121776000 | 13.81 |
| average payables | 26983000 | 17600500 | 53.31 |
| average inventory | 0 | -4165500 | 100.00 |
| days sales outstanding | 77.86 | 55.78 | 39.59 |
| days payables outstanding | 197.79 | 99.27 | 99.24 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 4.69 | 6.54 | -28.36 |
| payables turnover | 1.85 | 3.68 | -49.81 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.01 | -0.04 | 71.11 |
| capex per share | 0.14 | 0.13 | 1.63 |
ROE: Return on Equity (ROE) increased to -0.01 on 2023-12-31 from -0.04 on 2022-12-31, representing a change of 71.11%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -310.00 on 2023-12-31 from -58.61 on 2022-12-31, representing a change of -428.96%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 7.12 on 2023-12-31 from 12.05 on 2022-12-31, representing a change of -40.90%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.93 on 2023-12-31 from 0.88 on 2022-12-31, representing a change of 6.05%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| GDRX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.51 | 0.53 | -3.55 |
| net income per share | 0.03 | 0.02 | 81.49 |
| operating cash flow per share | 0.23 | 0.03 | 787.34 |
| free cash flow per share | 0.19 | -0.02 | 1034.71 |
| cash per share | 1.12 | 1.4 | -19.99 |
| book value per share | 1.83 | 1.78 | 3.10 |
| tangible book value per share | 0.61 | 0.24 | 152.68 |
| shareholders equity per share | 1.83 | 1.78 | 3.10 |
| interest debt per share | 0.18 | 1.92 | -90.48 |
| market cap | 2634888980 | 2942306280 | -10.45 |
| enterprise value | 2268085980 | 3124784280 | -27.42 |
| pe ratio | 53.73 | 109.89 | -51.10 |
| price to sales ratio | 13.49 | 14.67 | -7.99 |
| pocfratio | 30.33 | 303.3 | -90.00 |
| pfcf ratio | 37.11 | -390.85 | 109.49 |
| pb ratio | 3.78 | 4.4 | -13.92 |
| ptb ratio | 3.78 | 4.4 | -13.92 |
| ev to sales | 11.62 | 15.58 | -25.42 |
| enterprise value over ebitda | 59.68 | 84.81 | -29.63 |
| ev to operating cash flow | 26.11 | 322.11 | -91.89 |
| ev to free cash flow | 31.94 | -415.09 | 107.70 |
| earnings yield | 0.0 | 0.0 | 104.50 |
| free cash flow yield | 0.03 | -0.0 | 1153.23 |
| debt to equity | 0.08 | 1.06 | -92.26 |
| debt to assets | 0.04 | 0.48 | -91.23 |
| net debt to ebitda | -9.65 | 4.95 | -294.88 |
| current ratio | 5.48 | 7.32 | -25.17 |
| interest coverage | 1.65 | 1.42 | 16.69 |
| income quality | 21.91 | 1.45 | 1411.67 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.13 | 0.14 | -4.59 |
| research and ddevelopement to revenue | 0.15 | 0.15 | 0.36 |
| intangibles to total assets | 0.34 | 0.39 | -12.51 |
| capex to operating cash flow | 0.18 | 1.78 | -89.72 |
| capex to revenue | 0.08 | 0.09 | -5.43 |
| capex to depreciation | 0.9 | 1.02 | -10.94 |
| stock based compensation to revenue | 0.14 | 0.13 | 1.94 |
| graham number | 1.15 | 0.84 | 36.79 |
| roic | 0.01 | 0.01 | -6.76 |
| return on tangible assets | 0.01 | 0.01 | 84.54 |
| graham net net | -0.36 | -0.37 | 2.59 |
| working capital | 512439000 | 648082000 | -20.93 |
| tangible asset value | 231604000 | 90834000 | 154.98 |
| net current asset value | -31612000 | -55436000 | 42.98 |
| invested capital | 1019736000 | 1271035000 | -19.77 |
| average receivables | 160190500 | 175757500 | -8.86 |
| average payables | 14637500 | 25201000 | -41.92 |
| average inventory | 0 | 0.5 | -100.00 |
| days sales outstanding | 60.29 | 85.05 | -29.11 |
| days payables outstanding | 95.45 | 52.7 | 81.12 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 1.49 | 1.06 | 41.06 |
| payables turnover | 0.94 | 1.71 | -44.79 |
| inventory turnover | 0 | 0 | NaN |
| roe | 0.02 | 0.01 | 76.03 |
| capex per share | 0.04 | 0.05 | -8.78 |
ROE: Return on Equity (ROE) increased to 0.02 on 2024-09-30 Q3 from 0.01 on 2024-06-30 Q2, representing a change of 76.03%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 53.73 on 2024-09-30 Q3 from 109.89 on 2024-06-30 Q2, representing a change of -51.10%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 5.48 on 2024-09-30 Q3 from 7.32 on 2024-06-30 Q2, representing a change of -25.17%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.08 on 2024-09-30 Q3 from 1.06 on 2024-06-30 Q2, representing a change of -92.26%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Positive Sentiment: Discounted Cash Flow value is 7.72 which is higher than current price 4.57, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2025-01-13 18:00:20
GoodRx Holdings disclosed Monday (Jan. 13) that its chief financial officer, Karsten Voermann, submitted his resignation Tuesday (Jan. 7), effective Friday (Jan. 16). The company attributed the resignation to “personal reasons” in a Monday filing with the Securities and Exchange Commission.
Sentiment: Positive
Publish Date: 2025-01-10 11:00:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is offering free online healthcare provider visits to California residents impacted by the wildfires devastating Los Angeles County. Starting today, Angelenos can use the code LA-GOODRX-CARE to be seen by a licensed medical provider on GoodRx Care for a variety of conditions. Hundreds of thousands of Californians have been impacted by the wildfires, which may p.
Sentiment: Neutral
Publish Date: 2025-01-07 09:00:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced a new GoodRx for Pets experience that provides a more affordable and convenient way for Americans to access pet medications. Through GoodRx for Pets, pet owners can find savings and have pet medications delivered right to their door. GoodRx for Pets provides a seamless experience for pet owners, combining convenience, affordability, and accessibility in one place.
Sentiment: Neutral
Publish Date: 2024-12-18 16:05:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time). A live webcast will be available on the Company's Investor Relations website, https://investors.
Sentiment: Positive
Publish Date: 2024-12-16 16:05:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President and Chief Executive Officer, effective January 1, 2025. Wendy brings more than 30 years of leadership experience across the pharmacy and medical benefit industry to her new role. Wendy will join GoodRx following her role as CEO of RxBenefits, where she led the company in providing pharmacy benefit su.
Sentiment: Negative
Publish Date: 2024-12-05 09:00:01
Prescription fills for blockbuster weight loss medications in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments. That's according to new data from drug savings company GoodRx, which examined fill trends and spending patterns for weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Sentiment: Negative
Publish Date: 2024-12-05 09:00:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today released a new Weight Loss Medications Tracker that provides an inside look at fill trends and spending patterns for weight loss medications across the U.S. The company found that limited insurance coverage and high out-of-pocket costs aren't slowing down interest in popular drugs used for weight loss such as Mounjaro, Ozempic, Wegovy, and Zepbound. In fact, some of these p.
Sentiment: Positive
Publish Date: 2024-12-03 16:32:26
Mizuho analyst Steven Valiquette initiated coverage of GoodRx with a Neutral rating and $5 price target. Following an "upbeat analyst meeting" in May that included 6%-12% revenue compound annual growth rate guidance for 2024-2026, store closures announced this year by several large retail drug chains now negatively impact GoodRx's second half of 2024 and 2025 outlook, says the analyst, who believes this has already put 2026 guidance "in jeopardy."
Sentiment: Positive
Publish Date: 2024-11-18 09:00:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Helps, a 501(c)(3) nonprofit organization seeking to address health inequities across the country, has selected its 2024 Students for Healthcare Equity Scholarship recipients. The scholarship program was created to encourage culturally responsive healthcare by providing financial assistance to healthcare students from underrepresented groups. To date, GoodRx Helps has granted $325,000 in scholarships to students advocating for equitable access to he.
Sentiment: Positive
Publish Date: 2024-11-13 12:38:00
NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, GoodRx insiders caused the company to misrepresent or fail to disclose that (1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescription transactions revenue (the Company's primary revenue stream); and (2) Kroger could unilaterally cease accepting GoodRx discounts, cutting off some or all of GoodRx's revenues for purchases at Kroger's pharmacies; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
Sentiment: Positive
Publish Date: 2024-11-12 21:00:00
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company.
Sentiment: Positive
Publish Date: 2024-11-08 07:15:09
The company is growing key fundamentals. However, the improvements weren't enough to impress the market.
Sentiment: Neutral
Publish Date: 2024-11-07 14:14:19
GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript
Sentiment: Positive
Publish Date: 2024-11-07 10:35:53
While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sentiment: Positive
Publish Date: 2024-11-07 08:26:12
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago.
Sentiment: Neutral
Publish Date: 2024-11-07 06:05:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted.
Sentiment: Positive
Publish Date: 2024-11-06 10:20:39
Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Sentiment: Negative
Publish Date: 2024-11-05 15:44:33
Smaller pharmacies are accusing GoodRx and CVS of colluding to suppress generic prescription drug reimbursements. As Reuters reported Tuesday (Nov. 5), drug coupon aggregator GoodRx and a pair of pharmacy benefit managers (PBMs) — CVS's Caremark unit and Express Scripts — have all been named in at least three lawsuits by independent pharmacies.
Sentiment: Neutral
Publish Date: 2024-11-04 16:05:00
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at each of the following investor conferences: UBS 2024 Global Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 12, 2024 at 2 p.m. Eastern Time (11 a.m. Pacific Time) Citi 2024 Global Healthcare Conference in Miami, FL, on Thursday,.
Sentiment: Positive
Publish Date: 2024-10-31 15:17:00
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached their fiduciary duties to shareholders.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
